What type of study is this?

September 5, 2025Open Access

Figure S2 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

View Full Paper

Ask AI

Bookmark

POLB knockout does not induce synthetic lethality in cancer cell lines, indicating specific target interactions.
Viability was unaffected in POLB knockout cells, as shown by the CRISPR screening data from DepMap Public.
The findings highlight the importance of genetic context, specifically in BRCA-mutated tumors when considering PARP inhibition.
Research on POLB's role provides insights into cancer therapy strategies, emphasizing tailored approaches for different tumor types.

Implication

Supplementary analysis confirms POLB knockout does not cause synthetic lethality in cancer cell lines, suggesting distinct interactions in BRCA-mutated contexts.

Abstract

Supplementary Figure S2. POLB knockout alone does not induce synthetic lethality in cancer cell lines across multiple lineages - related to Figure 2. Viability is not impacted in POLB knockout cells as evidenced by the DepMap Public (Q1 2022) CRISPR screening data sets.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lazarides et al. (2025) studied this question.

synapsesocial.com/papers/68bb4e016d6d5674bcd028b0 https://doi.org/10.1158/1535-7163.30028937

View Full Paper

Ask AI

Bookmark

Implication

Supplementary analysis confirms POLB knockout does not cause synthetic lethality in cancer cell lines, suggesting distinct interactions in BRCA-mutated contexts.

Figure S2 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S2 from CRISPR Screens Identify POLB as a Synthetic Lethal Enhancer of PARP Inhibition Exclusively in BRCA-Mutated Tumors

Key Points

Implication

Abstract

Discussion

Cite This Study